Sarepta Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
I'm Matthew Harrison, one of the biopharma analysts here at Morgan Stanley. Very pleased to have Sarepta with us for the next session. Before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
And so with that, very pleased to have Doug Ingram, I'm the CEO; and Ian Estepan, the CFO from Sarepta. Doug, I'm going to turn it over to you to make some opening comments, and then we can get into Q&A.
Thank you.
Thank you very much, Matthew, and thanks for having us today. I think I made a promise in advance of the call that I will filibuster. So I'll be short. 2021 has been a very
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |